证券代码：300558 证券简称：贝达药业 公告编号：2024-009 一、股东股份质押基本情况 1、凯铭投资股份补充质押基本情况 | 股东 | 是否为控 股股东或 第一大股 | 本次质押 数量 | 占其所 持股份 | 占公司 总股本 | 是否为 | 是否为 | 质押 | 质押 | 质权人 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | | | 比例 | 比例 | 限售股 | 补充质押 | 起始日 | 到期日 | | 用途 | | | 东及其一 | （股） | | | | | | | | | | | 致行动人 | | | | | | | | | | | 凯铭 | 是 | 890,000 | 1.11% | 0.21% | 否 | 是 | 2024/1/31 | 2024/10/23 | 浙商证券 股份有限 | 补充 | | 投资 | | | | | | | | | | 质押 | | | | | | | | | | | 公司 | | | 凯铭 | 是 | 1,000,000 | 1.25% | 0 ...

Revenue and Profit Growth - Revenue for the third quarter reached RMB 729.67 million, a year-on-year increase of 78.24%[4] - Net profit attributable to shareholders of the listed company for the third quarter was RMB 156.39 million, a year-on-year increase of 1,833.29%[4] - Revenue for the first nine months of 2023 reached RMB 20,435.515 million, a year-on-year increase of 22.90%[11] - Net profit attributable to shareholders of the listed company for the first nine months of 2023 was RMB 3,046.929 million, a year-on-year increase of 196.38%[11] - Non-GAAP net profit attributable to shareholders of the listed company for the first nine months of 2023 was RMB 2,408.703 million, a year-on-year increase of 282.70%[11] - Total operating revenue increased to 2,043,551,452.90 yuan, up 22.9% compared to the previous year's 1,662,717,674.70 yuan[20] - Net profit surged to 294,122,417.51 yuan, a significant increase of 231.2% compared to 88,786,170.83 yuan in the previous year[21] - Basic earnings per share (EPS) increased to 0.73 yuan, up 192% from 0.25 yuan in the previous year[21] - Total comprehensive income rose to 302,555,436.99 yuan, a 116.5% increase from 139,729,957.02 yuan[21] R&D Investment and Innovation - Cumulative R&D investment from the beginning of the year to the end of the reporting period was RMB 729.93 million, accounting for 35.72% of revenue[6] - R&D investment for the first nine months of 2023 totaled RMB 7,299.267 million, accounting for 35.72% of revenue, a year-on-year increase of 4.58%[11] - MCLA-129 and Bifotinib Mesylate Capsule combination therapy, as well as EYP-1901 intravitreal implant, received clinical trial approval notices during the reporting period[12] - CFT8919 tablet drug clinical trial application was accepted during the reporting period[12] - R&D expenses decreased slightly to 467,939,305.01 yuan, down 2.9% from 481,915,519.12 yuan[20] Cash Flow and Financial Position - Net cash flow from operating activities for the first three quarters was RMB 559.99 million, a year-on-year increase of 167.07%[6] - Total assets as of the end of the reporting period were RMB 8.83 billion, an increase of 11.59% compared to the end of the previous year[4] - The company's monetary funds decreased from 731,284,859.68 yuan to 694,310,535.36 yuan as of September 30, 2023[17] - Accounts receivable increased from 433,313,912.37 yuan to 506,185,464.33 yuan as of September 30, 2023[17] - Long-term equity investments increased significantly from 107,767,074.61 yuan to 374,519,084.86 yuan as of September 30, 2023[17] - Total assets increased from 7,910,146,931.81 yuan to 8,827,265,054.73 yuan as of September 30, 2023[18] - Total liabilities increased from 2,952,445,102.86 yuan to 3,485,172,632.47 yuan as of September 30, 2023[18] - Shareholders' equity increased from 4,957,701,828.95 yuan to 5,342,092,422.26 yuan as of September 30, 2023[19] - The company's long-term borrowings increased significantly from 656,030,000.00 yuan to 1,733,200,000.00 yuan as of September 30, 2023[18] - The company's inventory decreased from 372,172,656.68 yuan to 340,675,676.16 yuan as of September 30, 2023[17] - The company's prepayments increased from 12,570,043.92 yuan to 32,676,024.02 yuan as of September 30, 2023[17] - Operating cash inflow increased to 2,139,574,472.81 RMB, up from 1,669,192,898.85 RMB in the previous period[23] - Net cash flow from operating activities rose to 559,988,099.54 RMB, compared to 209,680,381.29 RMB previously[23] - Cash outflow for investment activities totaled 1,260,612,771.96 RMB, a decrease from 1,419,244,622.44 RMB[23] - Net cash flow from financing activities was 635,249,145.58 RMB, down from 871,368,354.80 RMB[23] - Cash and cash equivalents at the end of the period stood at 731,284,859.68 RMB, compared to 791,989,554.14 RMB previously[23] - Cash received from other operating activities was 95,951,459.91 RMB, slightly down from 97,646,287.21 RMB[23] - Cash paid for goods and services decreased to 135,644,689.05 RMB from 170,845,079.75 RMB[23] - Cash paid to employees and for employee benefits increased to 431,619,614.07 RMB from 424,557,899.67 RMB[23] - Cash paid for taxes and fees rose to 72,585,574.66 RMB from 70,089,742.54 RMB[23] - Cash paid for other operating activities increased to 939,736,495.49 RMB from 794,019,795.60 RMB[23] Expenses and Costs - Sales expenses increased by 44.74% to RMB 709.52 million due to increased promotion costs for new products[7] - Sales expenses rose to 709,516,053.44 yuan, a 44.7% increase from 490,184,096.23 yuan[20] - Financial expenses increased significantly to 28,358,661.68 yuan, up 304.7% from 7,008,270.19 yuan[20] - Operating costs rose to 1,805,104,808.62 yuan, a 12.2% increase from 1,609,425,586.40 yuan in the previous year[20] Investments and Assets - Long-term loans increased by 164.20% to RMB 1.73 billion due to new bank loans[7] - Intangible assets increased by 33.12% to RMB 1.62 billion due to the approval and capitalization of new drug development costs[7] - Government subsidies received during the reporting period amounted to RMB 6.28 million[5] - Other non-current financial assets increased to RMB 150.00 million due to new investments in Beijing Mabworks Biotech Co., Ltd.[7] - The company invested RMB 150,000,041.64 to participate in the private placement of Beijing Mabworks Biotech Co., Ltd., acquiring 2,095,558 new shares, representing 2.91% of the total shares post-placement[12] Employee Incentives and Share Issuance - The company completed the registration of 1,018,840 restricted shares for the first vesting period of the 2021 restricted stock incentive plan, with 348 employees actually vesting[13] Other Financial Metrics - Other comprehensive income after tax decreased to 8,433,019.48 yuan, down 83.4% from 50,943,786.19 yuan[21] - Cash received from sales of goods and services reached 2,043,623,012.90 yuan, a 30.0% increase from 1,571,546,611.64 yuan[22]

贝达药业股份有限公司 2023 年半年度报告全文 1 | 第一节 | 重要提示、目录和释义 | 1 | | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | 5 | | 第三节 | 管理层讨论与分析 | 7 | | 第四节 | 公司治理 | 29 | | 第五节 | 环境和社会责任 | 31 | | 第六节 | 重要事项 | 46 | | 第七节 | 股份变动及股东情况 | 51 | | 第八节 | 优先股相关情况 | 56 | | 第九节 | 债券相关情况 | 57 | | 第十节 | 财务报告 | 58 | 贝达药业股份有限公司 2023 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人丁列明、主管会计工作负责人范建勋及会计机构负责人(会计 主管人员)王铁奇声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司 ...

Betta 20th Anniversary 贝贝纳 盐酸恩沙替尼胶 盐酸恩沙替尼胶囊 ) mg 演员给 25mg Thum 'E 展俄罗平封注影 班服份有限公司 attan 贝达荷业股份有限公司 盐酸埃克替尼片 (TOLIA π x 69 盐酸埃克替尼片 盐酸思沙替尼胶囊 些服务营品胶着 125mg 125mg 100mg 0111111111 一季度报告 2023年第- Quarterly Report 股票代码:300558 贝达药业股份有限公司 BETTA PHARMACEUTICALS CO., LTD. 贝达药业股份有限公司 2023 年第一季度报告 公司无需追溯调整或重述以前年度会计数据。 1 证券代码：300558 证券简称：贝达药业 公告编号：2023-047 贝达药业股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作 ...

Betta 20th Anniversary WXH 盐酸恩沙替尼胶囊 Ensartinib Hydroch 盐酸恩沙替尼胶囊 ) mg 31XH 25mg 16mg 时代早餐玩注册 祉般紛術館公司 盐酸埃克替尼片 xtin 贝达巴士殿的角周公告 (Dola 70.X 69 盐酸埃克替尼片 盐酸恩沙替尼胶囊 盐酸思沙블尼胶囊 125mg 125eg 21月/富× 100mg 2022年年度报告 Annual Report 股票代码:300558 贝达药业股份有限公司 BETTA PHARMACEUTICALS CO., LTD. 贝达药业股份有限公司 2022 年年度报告全文 目录 | --- | |---------------------------------------------------------------------------------------------------------------------------------------| | | | 第一节 重要提示、目录和释义……………………………………………………………………………………………………………………………………… ...